Status:
COMPLETED
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Lead Sponsor:
Pfizer
Conditions:
Thyroid Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participa...
Eligibility Criteria
Inclusion
- Histologically documented thyroid cancer with metastases.
- Failure of radioactive iodine (131I) to control the disease or radioactive iodine (131I) is not an appropriate therapy (e.g. due to lack of iodine uptake by the tumor)
Exclusion
- Central lung lesions involving major blood vessels (arteries or veins).(Central lesions that maintain the structural integrity of vessels have the potential to bleed if the tumor lesion undergoes necrosis. MRI or CT angiography should be used in any case where there is any question as to whether blood vessels are involved.)
- Patients with a history of hemoptysis
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00094055
Start Date
September 1 2004
End Date
January 1 2009
Last Update
June 26 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Santa Monica, California, United States, 90404
2
Pfizer Investigational Site
Aurora, Colorado, United States, 80010
3
Pfizer Investigational Site
Denver, Colorado, United States, 80220
4
Pfizer Investigational Site
Chicago, Illinois, United States, 60637